Search
Methods to generate stem cells have given scientists new ways to study some diseases and identify potential drugs, and could one day be used to rebuild diseased or damaged tissues in patients.
Understanding tumor heterogeneity may be the next big quest in cancer science, as differences between cells within a tumor can have important consequences for how cancers are diagnosed and treated.
In honor of Women's History Month, meet the scientific hero who helped build MSK's molecular biology program.
Patients with a rare but aggressive form of cancer now have access to a drug that has proven effective after the disease becomes resistant to standard treatments.
New research from MSK develops a method for analyzing cancer cells that survive treatment for acute myeloid leukemia; identifies a transcription factor that orchestrates natural killer cell response; and finds vepafestinib is a promising therapeutic for the treatment of RET-driven cancers.
New research from MSK explores novel predictors of immunotherapy effectiveness against lung cancer; identifies how a high-fat diet hinders intestinal damage repair; reports findings from a clinical trial for people with androgen receptor-positive salivary gland cancer; and aims to understand the impact of tumor mutational burden on patients with locally advanced non-small cell lung cancer.
Why do some patients respond to immunotherapy while others do not? Blood may hold the answer.
A team of researchers from MSK and Weill Cornell Medicine is expanding the understanding of how a decades-old treatment for bladder cancer works — an understanding that could help improve the effectiveness of immunotherapies more broadly.
Electronic nose (e-nose) technology identified early-stage lung cancer with high reliability in a prospective observational clinical trial conducted at Memorial Sloan Kettering Cancer Center (MSK).
Pancreatic cancer cells spread with the help of tracks laid by nerve-supporting cells called Schwann cells.